Cargando…
Clinical Experience with Insulin Detemir in Patients with Type 2 Diabetes from the Near East Countries
INTRODUCTION: This study aimed at determining the clinical safety and efficacy of insulin detemir (IDet) in combination with oral anti-diabetic drugs (OADs) in type 2 diabetes (T2D) patients from four Near East Countries (Israel, Jordan, Pakistan and Lebanon). METHODS: This prospective observational...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889319/ https://www.ncbi.nlm.nih.gov/pubmed/24108581 http://dx.doi.org/10.1007/s13300-013-0041-z |
_version_ | 1782299177873571840 |
---|---|
author | Echtay, Akram Tsur, Anat Hasan, Mohammad I. Abu-Hijleh, M. Omar Al Khatib, Nidal Andari, Emile Atallah, Paola Qureshi, Saleem Zafar, Jamal Sandalci, Levent Ademogulları, Asude Haddad, Jihad Dagan, Bracha |
author_facet | Echtay, Akram Tsur, Anat Hasan, Mohammad I. Abu-Hijleh, M. Omar Al Khatib, Nidal Andari, Emile Atallah, Paola Qureshi, Saleem Zafar, Jamal Sandalci, Levent Ademogulları, Asude Haddad, Jihad Dagan, Bracha |
author_sort | Echtay, Akram |
collection | PubMed |
description | INTRODUCTION: This study aimed at determining the clinical safety and efficacy of insulin detemir (IDet) in combination with oral anti-diabetic drugs (OADs) in type 2 diabetes (T2D) patients from four Near East Countries (Israel, Jordan, Pakistan and Lebanon). METHODS: This prospective observational study included T2D patients previously on OADs and newly diagnosed patients initiating IDet with or without OADs, at the discretion of physicians. Safety objectives included evaluation of hypoglycemia and adverse drug reactions (ADRs) from baseline to Week 24. Efficacy outcomes included baseline to Week 24 changes in glucose control parameters (glycated hemoglobin [HbA(1c)], fasting plasma glucose [FPG] and post-breakfast post-prandial plasma glucose [PPPG]). Change in body weight during this period was also assessed. RESULTS: A total of 2,155 patients (mean ± SD: age 57.1 ± 11.0 years, BMI 29.4 ± 5.1 kg/m(2), average diabetes duration 9.2 ± 5.4 years) were included. IDet dose at baseline was 0.20 ± 0.09 U/kg titrated up to 0.34 ± 0.14 U/kg by Week 24. From baseline to Week 24, the total number of hypoglycemic episodes increased from 1.30 to 1.37 events/patient-year, while major hypoglycemic episodes decreased from 0.15 to 0.02 events/patient-year. A total of 9 ADRs were reported, of which one event was a serious ADR. Statistically significant improvements in glucose control were reported from baseline to Week 24 (HbA(1c): 9.6 ± 1.6% vs. 7.6 ± 1.1%; FPG: 201.5 ± 59.5 mg/dL vs. 124.9 ± 31.6 mg/dL; PPPG: 264.2 ± 65.7 mg/dL vs. 167.2 ± 36.8 mg/dL; all p < 0.0001). Body weight did not change significantly after 24 weeks of IDet therapy. CONCLUSION: IDet therapy in combination with OADs improved glycemic control without increasing the risk of hypoglycemia or weight gain. |
format | Online Article Text |
id | pubmed-3889319 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-38893192014-01-14 Clinical Experience with Insulin Detemir in Patients with Type 2 Diabetes from the Near East Countries Echtay, Akram Tsur, Anat Hasan, Mohammad I. Abu-Hijleh, M. Omar Al Khatib, Nidal Andari, Emile Atallah, Paola Qureshi, Saleem Zafar, Jamal Sandalci, Levent Ademogulları, Asude Haddad, Jihad Dagan, Bracha Diabetes Ther Original Research INTRODUCTION: This study aimed at determining the clinical safety and efficacy of insulin detemir (IDet) in combination with oral anti-diabetic drugs (OADs) in type 2 diabetes (T2D) patients from four Near East Countries (Israel, Jordan, Pakistan and Lebanon). METHODS: This prospective observational study included T2D patients previously on OADs and newly diagnosed patients initiating IDet with or without OADs, at the discretion of physicians. Safety objectives included evaluation of hypoglycemia and adverse drug reactions (ADRs) from baseline to Week 24. Efficacy outcomes included baseline to Week 24 changes in glucose control parameters (glycated hemoglobin [HbA(1c)], fasting plasma glucose [FPG] and post-breakfast post-prandial plasma glucose [PPPG]). Change in body weight during this period was also assessed. RESULTS: A total of 2,155 patients (mean ± SD: age 57.1 ± 11.0 years, BMI 29.4 ± 5.1 kg/m(2), average diabetes duration 9.2 ± 5.4 years) were included. IDet dose at baseline was 0.20 ± 0.09 U/kg titrated up to 0.34 ± 0.14 U/kg by Week 24. From baseline to Week 24, the total number of hypoglycemic episodes increased from 1.30 to 1.37 events/patient-year, while major hypoglycemic episodes decreased from 0.15 to 0.02 events/patient-year. A total of 9 ADRs were reported, of which one event was a serious ADR. Statistically significant improvements in glucose control were reported from baseline to Week 24 (HbA(1c): 9.6 ± 1.6% vs. 7.6 ± 1.1%; FPG: 201.5 ± 59.5 mg/dL vs. 124.9 ± 31.6 mg/dL; PPPG: 264.2 ± 65.7 mg/dL vs. 167.2 ± 36.8 mg/dL; all p < 0.0001). Body weight did not change significantly after 24 weeks of IDet therapy. CONCLUSION: IDet therapy in combination with OADs improved glycemic control without increasing the risk of hypoglycemia or weight gain. Springer Healthcare 2013-10-10 2013-12 /pmc/articles/PMC3889319/ /pubmed/24108581 http://dx.doi.org/10.1007/s13300-013-0041-z Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Research Echtay, Akram Tsur, Anat Hasan, Mohammad I. Abu-Hijleh, M. Omar Al Khatib, Nidal Andari, Emile Atallah, Paola Qureshi, Saleem Zafar, Jamal Sandalci, Levent Ademogulları, Asude Haddad, Jihad Dagan, Bracha Clinical Experience with Insulin Detemir in Patients with Type 2 Diabetes from the Near East Countries |
title | Clinical Experience with Insulin Detemir in Patients with Type 2 Diabetes from the Near East Countries |
title_full | Clinical Experience with Insulin Detemir in Patients with Type 2 Diabetes from the Near East Countries |
title_fullStr | Clinical Experience with Insulin Detemir in Patients with Type 2 Diabetes from the Near East Countries |
title_full_unstemmed | Clinical Experience with Insulin Detemir in Patients with Type 2 Diabetes from the Near East Countries |
title_short | Clinical Experience with Insulin Detemir in Patients with Type 2 Diabetes from the Near East Countries |
title_sort | clinical experience with insulin detemir in patients with type 2 diabetes from the near east countries |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889319/ https://www.ncbi.nlm.nih.gov/pubmed/24108581 http://dx.doi.org/10.1007/s13300-013-0041-z |
work_keys_str_mv | AT echtayakram clinicalexperiencewithinsulindetemirinpatientswithtype2diabetesfromtheneareastcountries AT tsuranat clinicalexperiencewithinsulindetemirinpatientswithtype2diabetesfromtheneareastcountries AT hasanmohammadi clinicalexperiencewithinsulindetemirinpatientswithtype2diabetesfromtheneareastcountries AT abuhijlehmomar clinicalexperiencewithinsulindetemirinpatientswithtype2diabetesfromtheneareastcountries AT alkhatibnidal clinicalexperiencewithinsulindetemirinpatientswithtype2diabetesfromtheneareastcountries AT andariemile clinicalexperiencewithinsulindetemirinpatientswithtype2diabetesfromtheneareastcountries AT atallahpaola clinicalexperiencewithinsulindetemirinpatientswithtype2diabetesfromtheneareastcountries AT qureshisaleem clinicalexperiencewithinsulindetemirinpatientswithtype2diabetesfromtheneareastcountries AT zafarjamal clinicalexperiencewithinsulindetemirinpatientswithtype2diabetesfromtheneareastcountries AT sandalcilevent clinicalexperiencewithinsulindetemirinpatientswithtype2diabetesfromtheneareastcountries AT ademogullarıasude clinicalexperiencewithinsulindetemirinpatientswithtype2diabetesfromtheneareastcountries AT haddadjihad clinicalexperiencewithinsulindetemirinpatientswithtype2diabetesfromtheneareastcountries AT daganbracha clinicalexperiencewithinsulindetemirinpatientswithtype2diabetesfromtheneareastcountries |